UAB Insight Neurosciences Volume 1 - Page 2

N E W P H YS I C I A N S Brain Tumor SPORE Makes Four for UAB NEUROSCIENCES P U B L I C AT I O N S O F N OT E Alexandrov AV, Harrigan MR, et al. “Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis.” New England Journal of Medicine, 2011 Sept;365:993-1003. Nabors LB, Markert JM, Fiveash JB. “Patterns of Failure for Glioblastoma Multiforme Following Concurrent Radiation and Temozolomide.” Journal of Medical Imaging and Radiation Oncology, 2011 Feb;55(1):77-81. UAB Neurosurgeons Help Develop Acute Cervical Spine and Spinal Cord Injuries Guidelines The UAB Division of Watts RL, Guthrie BL. “Gene Delivery of AAV2-Neurturin for Parkinson’s Disease: A DoubleBlind, Randomised, Controlled Trial.” The Lancet Neurology, 2010 Dec;9(12):1164-1172. Oliva CR, Moellering DR, Gillespie GY, Griguer CE.“Acquisition of Chemoresistance in Gliomas Is Associated with Increased Mitochondrial Coupling and Decreased ROS Production.” PLoS One, 2011;6(9):e24665. UAB MEDICINE NEWS Neurosurgery and the UAB Standaert Appointed UAB Neurology Chair Health Image Exchange Opens Center have been awarded Movement disorders expert David Standaert, MD, PhD, The Central Alabama Health Image Exchange (CAHIE) a Specialized Program was named chair of the UAB Department of Neurology opened July 2011 with neurosurgeon Barton Guthrie, MD, of Research Excellence Three UAB neurosurgery physicians, including the two in August 2011. He is the director of the UAB Center as PI on a federal grant that helped develop the standards- (SPORE) grant from the for Neurodegeneration and Experimental Therapeutics, based system. It allows physicians at participating facilities cochairs, were among the seven-member group responsible National Cancer Institute for $2.3 million over three years to conduct research and the Division of Movement Disorders, and the UAB to share patients’ CT, MR, most cardiovascular, and other for writing the current Guidelines for Management of Acute Victor Sung, MD, joined UAB as imaging, as well as radiological reports. “Immediate access to Cervical Spine and Spinal Cord Injuries. Neurosurgeons Mark develop new therapies to treat brain tumors. Comprehensive Neuroscience Center. Standaert earned his medical and doctoral degrees from Washington University remote image data gives physicians vital data to support better centers in the nation with four SPORE programs—for brain, in St. Louis in medicine and pharmacology, respectively. care and mitigates the problem of trauma patients arriving breast, and pancreatic cancers, and a shared grant with Johns He completed his neurology residency at the University at UAB’s Level 1 Trauma Center with no prior imaging Hopkins University for cervical cancer. Only four institutions of Pennsylvania and a research and clinical fellowship in available,” says Guthrie. hold brain tumor SPORE grants. neurology at Harvard Medical School and Massachusetts assistant professor of neurology and received his MD from the University of Texas Southwestern Medical Center, Dallas. Postgraduate training consists of a UAB neurology residency, a movement disorders fellowship, and a Birmingham Veterans Affairs (VA) Medical Center VA National Quality Scholars fellowship. Hadley, MD, and Beverly Walters, MD, MSc, were cochairs, and pediatric neurosurgeon Curtis Rozzelle, MD, was a member of the group. The guidelines were developed under the auspices of and with the support of the Joint Section on Disorders of the UAB is one of an elite group of comprehensive cancer Translational scientist Yancey Gillespie, PhD, and Spine and Peripheral Nerves of the American Association neurosurgeon James Markert, MD, MPH, director, Division Surgeons. therapeutics for anaplastic gliomas. The award includes General Hospital and was a member of the Harvard faculty for Sontheimer Lab Suggests Origin, Treatment of 14 years before joining UAB in 2006. Glioma-related Seizures of Neurosurgery, co-lead the program to study contemporary UAB announced evidence in 2011 suggesting that excessive Markert Leads Southern Neurosurgery Society glutamate released from glioma cells causes epileptic activity James Markert Jr, MD, MPH, was elected president of the in peritumoral neurons, which may be stopped by glutamate- Southern Neurosurgery Society for 2011-2012. Markert, blocking drugs. The study, by researcher Harald Sontheimer, professor and director of the UAB Division of Neurosurgery, PhD, et al, established that the activity is associated with tumors is to develop and test a genetically engineered herpes earned his MD from Columbia University, NY, and completed glutamate release from the system xc(x)cystine-glutamate simplex virus (HSV) C134 to infect and kill brain tumor his internship and residency at the University of Michigan transporter expressed on tumor cells. The findings were or between treatment facilities,” cells while sparing normal brain cells. This chimeric third- Medical Center as well as a fellowship at Massachusetts published in September 2011 in Nature Medicine. says Hadley. generation virus was constructed by UAB pediatric infectious Frank Skidmore, MD, joined UAB as assistant professor of neurology and received his MD from the University of Virginia. Postgraduate training consists of an Indiana University Medical Center neurology residency and multiple sclerosis minifellowship; Johns Hopkins University School of Medicine neurosciences fellowship; and University of Maryland movement disorders fellowship. General Hospital, Boston. The author group reflected expertise in spinal neurosurgery, neurotrauma, and clinical epidemiology. “The management of these patients and their cord and vertebral column injuries typically had not been standardized or consistent within an institution $200,000 from the National Institutes of Neurological Disorders and Stroke to accelerate the initiation of two new clinical trials in the first year. One of primary objectives of the UAB SPORE in brain “We believe these guidelines disease specialist Kevin Cassady, MD, project leader. UAB define the variety of assessment researchers will establish the safety and high quality of the or treatment options available to virus preparation for the first-in-man clinical study. Markert, a clinician in the management project co-leader, has studied a similar, successful firstgeneration HSV in three phase 1 clinical trials at UAB. of an individual patient, provide A second project will test the ability of a UAB-produced direction within the broad scope F E AT U R E D CLINICAL TRIALS MEASURES OF SUCCESS Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) This randomized clinical study is designed to determine whether intracranial stenting (Wingspan stent) with intensive medical therapy is superior to the medical therapy alone for preventing second stroke in high-risk patients with symptomatic stenosis of a major intracranial artery. NCT00576693. PIs: Mark Harrigan, MD, and Andrei Alexandrov, MD. Contact: Lisa Nelson, RN 205.934.3131 or 205.975.9530. CLINICAL TRIALS monoclonal antibody (Tig atuzumab) to bind to human of clinical practice, highlight brain-tumor cells and cause them to be killed. UAB has what is known about specific conducted two previous clinical trials studying Tigatuzumab issues, and importantly, define in patients with other types of cancer. The project leaders are what is not known, in order to radiation biologist Donald J. Buchsbaum, PhD, and radiation stimulate additional research,” New guidelines promote he says. consistency in care. oncologist John Fiveash, MD. Pilot clinical projects of the UAB brain tumor SPORE will include design of a clinical trial to test a small-molecule inhibitor of a critical enzyme (JAK2) that is overactive in brain tumors, led by cell biologist Etty (Tika) Benveniste, PhD, and neuro-oncologist Burt Nabors, MD. continued from front page In the other clinical pilot project, pathologist Kevin Roth, neuroscience research is key to the university’s research is strong, and we are geographically well MD, PhD, and Nabors will test the safety and effectiveness inclusion in the network. He believes UAB’s positioned to recruit previously under-studied of the antimalaria drug quinacrine hydrochloride (Atabrine) strong programs in movement disorders, epilepsy, ethnic populations.” demyelinating diseases, and Alzheimer’s disease will be good targets for initial studies. Coprincipal investigator Khurram Bashir, MD, says, “UAB’s commitment to translational 2 UAB as associate professor of neurology, director of the UAB Division of Memory Disorders and Behavioral Neurology, and the Patsy W. and Charles A. Collat Scholar in Neuroscience. He was previously on the faculty of the University of Virginia Medical Center. He is the author of Contemporary Diagnosis and Management of Alzheimer’s Dementia. Comprehensive Cancer of Neurological Surgeons and the Congress of Neurological Walker HC, Watts RL, Guthrie BL, Montgomery EB, et al. “Activation of Subthalamic Neurons by Contralateral Subthalamic Deep Brain Stimulation in Parkinson Disease.” Journal of Neurophysiology, 2011 Mar;105:1112–1121. David Geldmacher, MD, joined F OR REF ERR A L S: 1- 8 0 0 - 8 2 2- 6 47 8 Massachusetts General Hospital is NeuroNEXT’s clinical coordinating center; the data coordinating center is hosted by the University of Iowa. in patients with anaplastic gliomas. Roth has shown that quinacrine blocks the ability of tumor cells to survive chemotherapy. The SPORE also will fund several pilot research projects to encourage development of additional novel therapies that also UAB Hospital’s seven-bed Seizure Monitoring Unit, managed by a separate Epilepsy Service, admits up to 50 patients every month. The Epilepsy Surgical will offer hope to patients with anaplastic gliomas. Program performs approximately 50 resections annually for patients from Alabama and adjacent states. Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression (PPMI) This observational, multicenter study assesses progression of clinical features, imaging, and biologic biomarkers in Parkinson disease (PD) patients compared to healthy controls (HC) and in PD patient subtypes, with the primary objective to find markers for use in clinical trials of disease-modifying therapies. NCT01141023. PI: David Standaert, MD, PhD. Contact: Stephanie Guthrie, 205.996.4033. MOR E INF OR M AT ION: /physician 3